Research Article

Clinical impact of the CYP3A5 6986A>G allelic variant on kidney transplantation outcomes

College de France, Laboratory of Central Neuropeptides in the Regulation of Body Fluid Homeostasis & Cardiovascular Functions, CIRB, INSERM U1050, Paris, France

Search for more papers by this author

Dany Anglicheau

Paris Descartes University, Sorbonne Paris Cité, INSERM UMRS 1147, Paris, France

Department of Nephrology & Kidney Transplantation, Necker Hospital, Assistance Publique Hôpitaux de Paris, Paris, France

Search for more papers by this author

Marie-Anne Loriot

Paris Descartes University, Sorbonne Paris Cité, INSERM UMRS 1147, Paris, France

Clinical Chemistry Department, Hôpital Européen Georges Pompidou Assistance Publique Hôpitaux de Paris, Paris, France

Search for more papers by this author

Eric Thervet

Paris Descartes University, Sorbonne Paris Cité, INSERM UMRS 1147, Paris, France

Department of Nephrology, Hôpital Européen Georges Pompidou, Assistance Publique Hôpitaux de Paris, Paris, France

Search for more papers by this author

Nicolas Pallet

*Author for correspondence:

E-mail Address: npallet@yahoo.fr

Paris Descartes University, Sorbonne Paris Cité, INSERM UMRS 1147, Paris, France

Clinical Chemistry Department, Hôpital Européen Georges Pompidou Assistance Publique Hôpitaux de Paris, Paris, France

Search for more papers by this author

Published Online:15 Dec 2016https://doi.org/10.2217/pgs-2016-0146

View article

Abstract

Aim: Meta-analyses and large cohort studies provide confusing results on the association of the CYP3A5 6986A>G allelic variant and adverse outcomes in kidney transplant recipients under tacrolimus-based immunosuppressive regimen. A residual effect of CYP3A5 recipient genotype is unexpected if kidney transplant recipients have similar exposure of tacrolimus. Patients & methods: We have undertaken a population-based, observational study, to investigate all the consecutive patients who received a kidney transplant at the Necker hospital between 2005 and 2015, who were treated with tacrolimus and for whom the CYP3A5 genotype was available. Results & conclusion: We analyzed 577 patients followed for up to 5 years. We found a significant association of CYP3A5 genotypes with tacrolimus daily dose as well as with tacrolimus dose-adjusted concentrations. We however found no association of CYP3A5 genotypes with histology scores on biopsies, measured renal function, biopsy-proven acute rejection episodes and graft survival.

Keywords:

References

1 Thervet E, Anglicheau D, King B et al. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 76(8), 1233–1235 (2003).Crossref, Medline, CAS, Google Scholar
2 Elens L, Bouamar R, Hesselink DA et al. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin. Chem. 57(11), 1574–1583 (2011).Crossref, Medline, CAS, Google Scholar
3 Rojas L, Neumann I, Herrero MJ et al. Effect of CYP3A5*3 on kidney transplant recipients treated with tacrolimus: a systematic review and meta-analysis of observational studies. Pharmacogenomics J. 15(1), 38–48 (2015).Crossref, Medline, CAS, Google Scholar
4 Wallemacq P, Armstrong VW, Brunet M et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Ther. Drug Monit. 31(2), 139–152 (2009).Crossref, Medline, CAS, Google Scholar
5 Thervet E, Loriot MA, Barbier S et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin. Pharmacol. Ther. 87(6), 721–726 (2010).Medline, CAS, Google Scholar
6 Pallet N, Etienne I, Buchler M et al. Long-term clinical impact of adaptation of initial tacrolimus dosing to CYP3A5 genotype. Am. J. Transplant. 16(9), 2670–2675 (2016).Crossref, Medline, CAS, Google Scholar
7 Shuker N, Bouamar R, van Schaik RHN et al. A randomized controlled trial comparing the efficacy of CYP3A5 genotype-based with body-weight-based tacrolimus dosing after living donor kidney transplantation. Am. J. Transplant. 16(7), 2085–2096 (2016).Crossref, Medline, CAS, Google Scholar
8 Ekberg H, Bernasconi C, Tedesco-Silva H et al. Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation. Am. J. Transplant. 9(8), 1876–1885 (2009).Crossref, Medline, CAS, Google Scholar
9 Ekberg H, Tedesco-Silva H, Demirbas A et al. Reduced exposure to calcineurin inhibitors in renal transplantation. New Engl. J. Med. 357(25), 2562–2575 (2007).Crossref, Medline, CAS, Google Scholar
10 Kuypers DRJ, Naesens M, de Jonge H, Lerut E, Verbeke K, Vanrenterghem Y. Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients. Ther. Drug Monit. 32(4), 394–404 (2010).Crossref, Medline, CAS, Google Scholar
11 Glowacki F, Lionet A, Buob D et al. CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on tacrolimus dose requirements and clinical outcome after renal transplantation. Nephrol. Dial. Transplant. 26(9), 3046–3050 (2011).Crossref, Medline, CAS, Google Scholar
12 Terrazzino S, Quaglia M, Stratta P, Canonico PL, Genazzani AA. The effect of CYP3A5 6986A>G and ABCB1 3435C>T on tacrolimus dose-adjusted trough levels and acute rejection rates in renal transplant patients: a systematic review and meta-analysis. Pharmacogenet. Genomics 22(8), 642–645 (2012).Crossref, Medline, CAS, Google Scholar
13 Gijsen VMGJ, Madadi P, Dube MP, Hesselink DA, Koren G, de Wildt SN. Tacrolimus-induced nephrotoxicity and genetic variability: a review. Ann. Transplant. 17(2), 111–121 (2012).Crossref, Medline, Google Scholar
14 Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 150(9), 604–612 (2009).Crossref, Medline, Google Scholar
15 Haas M, Sis B, Racusen LC et al. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am. J. Transplant. 14(2), 272–283 (2014).Crossref, Medline, CAS, Google Scholar
16 Bates D, Mächler M, Bolker B, Walker B. Fitting linear mixed-effects models using lme4. J. Stat. Software (Online), 67. www.jstatsoft.org/article/view/v067i01Google Scholar
17 R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing. Vienna, Austria. www.R-project.org/.Google Scholar
18 Quaranta S, Chevalier D, Allorge D et al. Ethnic differences in the distribution of CYP3A5 gene polymorphisms. Xenobiotica 36(12), 1191–1200 (2006).Crossref, Medline, CAS, Google Scholar
19 Snanoudj R, Royal V, Elie C et al. Specificity of histological markers of long-term CNI nephrotoxicity in kidney-transplant recipients under low-dose cyclosporine therapy. Am. J. Transplant. 11(12), 2635–2646 (2011).Crossref, Medline, CAS, Google Scholar
20 Naesens M, Kuypers DRJ, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin. J. Am. Soc. Nephrol. 4(2), 481–508 (2009).Crossref, Medline, CAS, Google Scholar
21 MacPhee IAM, Fredericks S, Tai T et al. The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am. J. Transplant. 4(6), 914–919 (2004).Crossref, Medline, CAS, Google Scholar
22 Pollock-Barziv SM, Finkelstein Y, Manlhiot C et al. Variability in tacrolimus blood levels increases the risk of late rejection and graft loss after solid organ transplantation in older children. Pediatr. Transplant. 14(8), 968–975 (2010).Crossref, Medline, Google Scholar
23 O'Regan JA, Canney M, Connaughton DM et al. Tacrolimus trough-level variability predicts long-term allograft survival following kidney transplantation. J. Nephrol. 29(2), 269–276 (2016).Crossref, Medline, Google Scholar
24 Gourishankar S, Leduc R, Connett J et al. Pathological and clinical characterization of the ‘troubled transplant’: data from the DeKAF study. Am. J. Transplant. 10(2), 324–330 (2010).Crossref, Medline, CAS, Google Scholar
25 Matas AJ, Leduc R, Rush D et al. Histopathologic clusters differentiate subgroups within the nonspecific diagnoses of CAN or CR: preliminary data from the DeKAF Study. Am. J. Transplant. 10(2), 315–323 (2010).Crossref, Medline, CAS, Google Scholar
26 El-Zoghby ZM, Stegall MD, Lager DJ et al. Identifying specific causes of kidney allograft loss. Am. J. Transplant. 9(3), 527–535 (2009).Crossref, Medline, CAS, Google Scholar

Vol. 18, No. 2

Supplemental Materials

Metrics

Downloaded 202 times

History

Published online 15 December 2016

Published in print January 2017

Information

Keywords

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.

PDF download